Critical size defect regeneration by rhPTH-collagen membrane as a new tissue engineering tool

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 12, 2014, Pages 4358-4364

  Missana, Liliana R ^a,b   Jammal, María V ^a,b  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

^b PLANTA PILOTO DE PROCESOS INDUSTRIALES MICROBIOLÓGICOS PROIMI CONICET   (Argentina)

Author keywords

Bone regeneration; Critical size defect; Grafts; RhPTH; Type I atelocollagen

Indexed keywords

BIOLOGICAL MATERIALS; BONE; DEFECTS; GRAFTS; MEMBRANES; TISSUE; TISSUE ENGINEERING;

ATELOCOLLAGEN; BONE REGENERATION; COLLAGEN MEMBRANE; CRITICAL SIZE DEFECT; DELIVERY SYSTEMS; PARATHYROID HORMONES; RHPTH; STATISTICAL DIFFERENCES;

TISSUE REGENERATION;

ATELOCOLLAGEN; COLLAGEN; RECOMBINANT PARATHYROID HORMONE; ARTIFICIAL MEMBRANE; PARATHYROID HORMONE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY OSSICLE; BODY WEIGHT; BONE REGENERATION; CALVARIA; CONTROLLED STUDY; CRITICAL SIZE DEFECT; DRUG EFFICACY; FEMALE; HISTOMETRY; NONHUMAN; OSSIFICATION; RAT; TISSUE ENGINEERING; WISTAR RAT; ANIMAL; ARTIFICIAL MEMBRANE; BONE DEVELOPMENT; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; PROCEDURES;

ANIMALS; BONE REGENERATION; COLLAGEN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MEMBRANES, ARTIFICIAL; OSTEOGENESIS; PARATHYROID HORMONE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TISSUE ENGINEERING;

EID: 84911805411     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35114     Document Type: Article

References (26)

1. Dahlin C, Linde A, Gottlow J, Nyman S. Healing of bone defects by guided tissue regeneration. Plat Reconstr Surg 1988;81:672-676.
2. Dupoirieux L, Pourquier D, Picot M, Neves M. Comparative study of three different membranes for guided bone regeneration of rat cranial defects. Int J Oral Maxillofac Surg 2001;30:58-62.
3. Shi S, Kirk M, Kahn A. The role of type I collagen in the regulation of osteoblast phenotype. J Bone Mineral Res 1996;11:735-742.
4. Rodriguez A, Missana L, Nagatsuka H, Gunduz M, Tsujigiwa H, Rivera R, Nagai N. Efficacy of atelocollagen honeycomb scaffold in bone formation using KUSA/A1 cells. J Biomed Mater Res A 2006;77:707-717.
5. Hodsman A, Bauer D, Dempster D, Dian L, Harris S, Kendler D, McClung M, Miller P, Olszynski W, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
6. Nakazawa T, Nakajima A, Shiomi K, Moriya H, Einhorn T, Yamazaki M. Effects of low dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fractures healing. Bone 2005;37: 711-719.
7. Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, Seki A, Sun Y, Yamamoto T. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 2007;40:1475-1482.
8. Rowshan H, Parham M, Baur D, McEntee R, Cauley E, Carriere D, Wood J, Demsar W, Pizarro J. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats.J Oral Maxillofac Surg. 2010; 68:260-267.
9. Jammal MV, Pastorino N, Abate C Missana L. Bone-healing pattern on critical-sized defects treated by rhPTH. J Hard Tissue Biol 2012;4:443-450.
10. Kamo K, Miyakoshi N, Kasukawa Y, Nozaka K, Sasaki H, Shimada Y. Intermittent weekly administration of human parathyroid hormone (1-34) improves bone-hydroxyapatite block bonding in ovariectomized rats. J Bone Miner Metab 2010;28:634-640.
11. Andreassen T, Cacciafesta V. Intermittent parathyroid hormone treatment enhances guided bone regeneration in rat calvarial bone defects. J Craniofacial Surg 2004;15:424-427.
12. Yun J, Wikesjö U, Borke J, Bisch F, Lewis J, Herold R, Swiec G, Wood J, McPherson J III. Effect of systemic parathyroid hormone (1-34) and a beta-tricalcium phosphate biomaterial on local bone formation in a critical-size rat calvarial defect model. J Clin Periodontol 2010;37:419-426.
13. Wei G, Pettway G, McCauley L, Ma P. The release profiles and bioactivity of parathyroid hormone from poly (lactic-co-glycolic acid) microspheres. Biomaterials 2004;25:345-352.
14. Backstrom K, Bertone A, Wisner E, Weisbrode S. Response of induced bone defects in horses to collagen matrix containing the human parathyroid hormone gene. Am J Vet Res 2004;9:1223-1232.
15. Jung R, Cochran D, Domken O, Seibl R, Jones A, Buser D, Hammerle C. The effect of matrix bound parathyroid hormone on bone regeneration. Clin Oral Implants Res 2007;18:319-325.
16. Missana L, Nagai N, Kuboki Y. Comparative histological studies of bone and cartilage formations induced by various BMP-carriers composites. Jpn J Oral Biol 1994;36:9-19.
17. Roberts W. Fundamental principles of bone physiology, metabolism and loading. In: Naert I, Van Steenberghe D, Worthington P, editors. Osseointegration in Oral Rehabilitation. Carol Stream, IL: Quintessence Publishing; 1993. p 157-170.
18. Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniomandibular nonunions. Clin Orthopaedics Related Res 1986;205:299-308.
19. Aybar A, Territoriale E, Missana L. Animal model in calvaria to evaluate bone strategies. Acta Odontológica Latinoamericana 2005;18:21-25.
20. Jammal M, Territoriale E, Abate C, Missana L. High resolution films for bone regeneration evaluation. Acta Odontológica Latinoamericana 2010;23:33-36.
21. Vahle J, Sato M, Long G, Young J, Francis P, Engelhardt J, Westmore M, Linda Y and Nold J. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicologic Pathol 2002;30:312-321.
22. Vahle J, Long G, Sandusky G, Westmore M, Ma L, Sato M. Bone neoplasms in F344 rats given teriparatide (rhPTH 1-34) are dependent on duration of treatment and dose. Toxicologic Pathol 2004;32:426-438.
23. Jollette J, Wilker C, Smith S, Doyle N, Hardisty J, Metcalfe A, Marriott T, Fox J, Wells D. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicologic Pathol 2006;34:929-940.
24. Whitfield JF, Morley P, Willick GE. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat Endocrinol 2002;1:175-190.
25. Zhang W, Chen J, Tao J, Hu C, Chen L, Zhao H, Xu G, Heng BC, Ouyang HW. The promotion of osteochondral repair by combined intra-articular injection of parathyroid hormone-related protein and implantation of a bi-layer collagen-silk scaffold. Biomaterials 2013;25:6046-6057.
26. Jung R, Hämmerle C, Kokovic V, Weber F. Bone regeneration using a synthetic matrix containing a parathyroid hormone peptide combined with a grafting material. Int J Oral Maxillofac Implants 2007;22:258-266.